Mark Plavsic

Mark Plavsic

Company: Fate Therapeutics

Job title: Chief Technical Officer

Seminars:

Manufacturing of Next-Generation Cellular Immunotherapies using a Novel Induced Pluripotent Stem Cell Platform 11:45 am

Outline advantage of iPSC derived platform Discuss some challenges Review potential scale up opportunitiesRead more

day: Day One

Panel: The Bigger Picture: The Priorities of iPSC Based Cell Therapy Manufacturing 8:30 am

Identifying areas of focus during different developmental stages to ensure successful iPSC production and scale-up Managing operations and mitigating risk to ensure smooth transition through preclinical and clinical phasesRead more

day: Day One

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.